Search - tctmd.com

Displaying 21 - 40 of 356

Sort: Relevancy | Date

ARNI Lessens Anthracycline Cardiotoxicity in High-Risk Patients: SARAH

News Conference News AHA 2024

ARNI Lessens Anthracycline Cardiotoxicity in High-Risk Patients: SARAH

November 18, 2024

ENBALV: Edoxaban Matches Warfarin After Bioprosthetic Valve Surgery

News Conference News AHA 2024

ENBALV: Edoxaban Matches Warfarin After Bioprosthetic Valve Surgery

Yael L. Maxwell

November 17, 2024

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

News Conference News VIVA 2024

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

November 11, 2024

After TAVI, Single Antiplatelet Better Than Dual: TRITAVI Registry

News Conference News TCT 2024

After TAVI, Single Antiplatelet Better Than Dual: TRITAVI Registry

Yael L. Maxwell

November 05, 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

November 05, 2024

News Conference News TCT 2024

Bleeding After MCS in DanGer Shock: When, Where, and What to Do?

October 31, 2024

More Registry Data Show Post-TAVI Benefits With Sentinel but No Stroke Impact

News Conference News TCT 2024

More Registry Data Show Post-TAVI Benefits With Sentinel but No Stroke Impact

Yael L. Maxwell

October 28, 2024

LAAO Outcomes Similar Regardless of Operator’s Specialty

News Conference News TCT 2024

LAAO Outcomes Similar Regardless of Operator’s Specialty

October 27, 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

News Conference News HFSA 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

October 01, 2024

More Support for Ticagrelor Monotherapy After PCI, Especially in ACS

News Conference News ESC 2024

More Support for Ticagrelor Monotherapy After PCI, Especially in ACS

Yael L. Maxwell

September 10, 2024

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

News Conference News ESC 2024

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

Michael O'Riordan

September 09, 2024

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

News Conference News ESC 2024

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

September 01, 2024

NOTION-3: PCI Before TAVI Lowers MACE Risks in Patients With Significant CAD

News Conference News ESC 2024

NOTION-3: PCI Before TAVI Lowers MACE Risks in Patients With Significant CAD

Michael O'Riordan

September 01, 2024

Polypills Show Promise in Diverse Hypertensive Patient Groups

News Conference News ESC 2024

Polypills Show Promise in Diverse Hypertensive Patient Groups

August 31, 2024

Aveir DR Dual-Chamber Leadless Pacemaker Looks Solid at 1 Year

News Conference News HRS 2024

Aveir DR Dual-Chamber Leadless Pacemaker Looks Solid at 1 Year

May 23, 2024

TEMPO-2: Tenecteplase No Help in Mild Stroke With Proven Occlusion

News Conference News ESOC 2024

TEMPO-2: Tenecteplase No Help in Mild Stroke With Proven Occlusion

May 23, 2024

More Trial Evidence Supports Tenecteplase for Acute Stroke Thrombolysis

News Conference News ESOC 2024

More Trial Evidence Supports Tenecteplase for Acute Stroke Thrombolysis

May 21, 2024

OCT-Based Strategy Outperforms Angiography in Calcified Lesions: CALIPSO

News Conference News EuroPCR 2024

OCT-Based Strategy Outperforms Angiography in Calcified Lesions: CALIPSO

May 16, 2024

ShortCut Leaflet Splitter Proves Safe, May Streamline Valve-in-Valve TAVI

News Conference News EuroPCR 2024

ShortCut Leaflet Splitter Proves Safe, May Streamline Valve-in-Valve TAVI

May 16, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.